Function
Locations
Final step of de novo dolichol synthesis. Deficiency = SRD5A3-CDG (CDG-Iq; ocular coloboma, cerebellar involvement).
Assembly of the dolichol-linked oligosaccharide (and of GPI anchors, O- and C-mannosylation) depends on a dolichyl-phosphate lipid carrier and on two lipid-linked monosaccharide donors, dolichyl-phosphate-mannose (Dol-P-Man) and dolichyl-phosphate-glucose (Dol-P-Glc). This module curates their supply at the endoplasmic-reticulum membrane. The polyprenol reductase SRD5A3 catalyses the last step of de novo dolichol synthesis, reducing the alpha-isoprene unit of polyprenol to dolichol; dolichol kinase DOLK then phosphorylates dolichol (using CTP) to dolichyl phosphate (Dol-P), the essential carrier. Dol-P is charged with sugars by two systems: the dolichol-phosphate-mannose (DPM) synthase, a three-subunit complex in which DPM1 is the GDP-mannose-utilising catalytic subunit and DPM2 (regulatory/stabilising) and DPM3 (membrane anchor for the TM-less DPM1) are non-catalytic, produces Dol-P-Man from GDP-mannose and Dol-P; and ALG5 (dolichyl-phosphate beta-glucosyltransferase) produces Dol-P-Glc from UDP-glucose and Dol-P. The utilisation factor MPDU1 (Lec35) is then required for these lipid-linked donors to be used by the lumenal glycosyltransferases. Because they feed the whole glycosylation system, defects in every gene here cause a congenital disorder of glycosylation: SRD5A3-CDG (CDG-Iq), DOLK-CDG (CDG-Im, dilated cardiomyopathy), DPM1-CDG (CDG-Ie), DPM2-CDG (CDG-Iu) and DPM3-CDG (CDG-Io) — the latter two dystroglycanopathies — MPDU1-CDG (CDG-If) and ALG5-CDG.
All recommended fields populated.
✗ none found
No MODULE:dolichol_phosphate_sugar_donor_supply deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
7 complete review(s) · 0 with deep research · 0 missing review · 7 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| ALG5 Q9Y673 | ✓ | ✓ | ✗ |
| DOLK Q9UPQ8 | ✓ | ✓ | ✗ |
| DPM1 O60762 | ✓ | ✓ | ✗ |
| DPM2 O94777 | ✓ | ✓ | ✗ |
| DPM3 Q9P2X0 | ✓ | ✓ | ✗ |
| MPDU1 O75352 | ✓ | ✓ | ✗ |
| SRD5A3 Q9H8P0 | ✓ | ✓ | ✗ |
Dolichyl-phosphate and lipid-linked sugar-donor supply, grounded to the human enzymes SRD5A3 (UniProtKB:Q9H8P0, GO:0160198, EC 1.3.1.94), DOLK (Q9UPQ8, GO:0004168, EC 2.7.1.108), the DPM synthase complex (DPM1 O60762 GO:0004582 catalytic EC 2.4.1.83, DPM2 O94777 GO:0008047 regulatory, DPM3 Q9P2X0 GO:0043495 anchor; complex GO:0033185), ALG5 (Q9Y673, GO:0004581, EC 2.4.1.117) and MPDU1 (O75352, non-catalytic utilisation factor). GO molecular-function/BP/location terms were taken from the completed human gene reviews and verified against the local go.db; Reactome reaction ids/titles were verified against the local reactome cache. Each step uses a PANTHER family selector with the human protein as representative so the module generalises across orthologs/paralogs; the DPM synthase is modelled as a PROTEIN_COMPLEX node (one catalytic + two non-catalytic subunits). Note SRD5A3 is a polyprenol reductase, not a physiological steroid 5alpha-reductase despite its name; MPDU1 (Lec35) has no informative molecular-function term and is represented by its BP role. This module supplies the Dol-P carrier (used by DPAGT1 and the cytoplasmic LLO module) and the Dol-P-Man / Dol-P-Glc donors (used by the lumenal LLO module ALG3/ALG9/ALG12 and ALG6/ALG8/ ALG10), and also feeds GPI-anchor and O-/C-mannosylation. Disorders: every gene is a CDG type I (SRD5A3-, DOLK-, DPM1-, DPM2-, DPM3-, MPDU1-, ALG5-CDG), with DPM2-/DPM3-CDG presenting as muscular dystrophy-dystroglycanopathies and DOLK-CDG as dilated cardiomyopathy.
Final step of de novo dolichol synthesis. Deficiency = SRD5A3-CDG (CDG-Iq; ocular coloboma, cerebellar involvement).
Produces the Dol-P carrier used by DPM synthase, ALG5, DPAGT1 and GPI/O-mannosylation. Deficiency = DOLK-CDG (CDG-Im; dilated cardiomyopathy).
Catalytic subunit; deficiency = DPM1-CDG (CDG-Ie).
Regulatory/stabilising subunit; deficiency = DPM2-CDG (dystroglycanopathy).
Membrane-anchoring subunit; deficiency = DPM3-CDG (dystroglycanopathy).
Makes the Dol-P-Glc glucose donor for the lumenal LLO glucosylation steps. Deficiency = ALG5-CDG.
Non-catalytic utilisation/presentation factor enabling lumenal use of Dol-P-Man and Dol-P-Glc. MPDU1 has no informative molecular-function term (no F-aspect GOA annotation); represented here by its biological-process role.